Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

BACKGROUND: Increased prevalence of metabolic syndrome (MS) is observed in psoriasis. Metformin has shown improvement in cardiovascular risk factors while pioglitazone demonstrated anti proliferative, anti-inflammatory and anti angiogenic effects. Study objective is to evaluate the efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Surjit, Bhansali, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987981/
https://www.ncbi.nlm.nih.gov/pubmed/27531132
http://dx.doi.org/10.1186/s12895-016-0049-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987981/
https://www.ncbi.nlm.nih.gov/pubmed/27531132
http://dx.doi.org/10.1186/s12895-016-0049-y

Ejemplares similares